ACTIVATION AND REGULATION OF THE HER2 AND HER4 KINASES

HER2 和 HER4 激酶的激活和调节

• 批准号: 8361419
• 负责人: RON BOSE
• 金额: $ 4.36万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361419
• 关键词: Biochemistry; Breast; Cancer Patient; Cellular biology; Drug Delivery Systems; Drug resistance; ERBB2 gene; Epidermal Growth Factor Receptor; ErbB4 gene; Family; Funding; Genes; Grant; Growth; Growth Factor Receptors; Human; Malignant Neoplasms; Mass Spectrum Analysis; Monoclonal Antibodies; National Center for Research Resources; Neoplasm Metastasis; Patients; Phosphotransferases; Play; Principal Investigator; Protein Tyrosine Kinase; Proteomics; Regulation; Research; Research Infrastructure; Resources; Role; Signal Transduction Pathway; Source; United States National Institutes of Health; biomedical resource; cost; erbB-2 Receptor; extracellular; improved; kinase inhibitor; malignant breast neoplasm; member; receptor; small molecule

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Alterations of signal transduction pathways play a significant role in the growth and metastasis of human cancers. We focus on the Her2/neu receptor tyrosine kinase, a member of the EGFR growth factor receptor family, which is gene amplified and activated in about 25% of human breast cancer cases. Several drugs that target Her2/neu are used in the treatment of Her2-positive breast cancer, such as a monoclonal antibody to the extracellular portion of the receptor or small molecule kinase inhibitors, but resistance to these drugs has frequently been seen in patients. Better understanding of Her2/neu and the downstream signal transduction pathways it uses will provide improved treatment for breast cancer patients. Our lab studies signal transduction pathways in breast cancer using a variety of approaches involving biochemistry, proteomics, and cell biology.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 信号转导途径的改变在人类癌症的生长和转移中起着重要作用。我们专注于HER2/NEU受体酪氨酸激酶，EGFR生长因子受体家族的成员，该基因在大约25％的人类乳腺癌病例中被基因扩增和激活。靶向HER2/NEU的几种药物用于治疗HER2阳性乳腺癌，例如与受体细胞外部分或小分子激酶抑制剂的单克隆抗体，但患者经常看到对这些药物的耐药性。更好地了解HER2/NEU及其使用的下游信号转导途径将为乳腺癌患者提供改进的治疗方法。 我们的实验室研究使用涉及生物化学，蛋白质组学和细胞生物学的各种方法在乳腺癌中信号转导途径。